-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Vonafexor
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/1192171-69-9.gif)
| Category | Hepatitis B Virus (HBV) |
| CAS | 1192171-69-9 |
| Description | Vonafexor is an orally bioavailable synthetic non-steroidal, non-bile acid, second-generation farnesoid X receptor (FXR) agonist. |
Product Information
| Synonyms | PLX007; EYP001 |
| IUPAC Name | 4-chloro-5-[4-(2,6-dichlorophenyl)sulfonylpiperazin-1-yl]-1-benzofuran-2-carboxylic aci |
| Molecular Weight | 489.76 |
| Molecular Formula | C19H15Cl3N2O5S |
| Canonical SMILES | C1CN(CCN1C2=C(C3=C(C=C2)OC(=C3)C(=O)O)Cl)S(=O)(=O)C4=C(C=CC=C4Cl)Cl |
| InChI | InChI=1S/C19H15Cl3N2O5S/c20-12-2-1-3-13(21)18(12)30(27,28)24-8-6-23(7-9-24)14-4-5-15-11(17(14)22)10-16(29-15)19(25)26/h1-5,10H,6-9H2,(H,25,26) |
| InChIKey | XLGQSYUNOIJBNR-UHFFFAOYSA-N |
| Purity | 99.87% |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | Off-white to light yellow (Solid) |
| Storage | Powder: -20°C: 3 years 4°C: 2 years In solvent: -80°C: 6 months -20°C: 1 month |
| Complexity | 733 |
| Exact Mass | 487.976726 |
| In Vitro | Vonafexor (EYP001) inhibits the HBV replication cycle in HepaRG cells resulting in significant reductions in HBV DNA, HBsAg and HBeAg secretion, with additive effects when combined with Entecavir (HY-13623) or Tenofovir (HY-13910). |
| Target | FXR; HBV |
| XLogP3-AA | 4.8 |
